MX2021001606A - Tratamiento de la malignidades de las celulas b. - Google Patents

Tratamiento de la malignidades de las celulas b.

Info

Publication number
MX2021001606A
MX2021001606A MX2021001606A MX2021001606A MX2021001606A MX 2021001606 A MX2021001606 A MX 2021001606A MX 2021001606 A MX2021001606 A MX 2021001606A MX 2021001606 A MX2021001606 A MX 2021001606A MX 2021001606 A MX2021001606 A MX 2021001606A
Authority
MX
Mexico
Prior art keywords
treatment
cell malignancies
pi3k
inhibitor
administered
Prior art date
Application number
MX2021001606A
Other languages
English (en)
Spanish (es)
Inventor
Daniel P Gold
Original Assignee
Mei Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mei Pharma Inc filed Critical Mei Pharma Inc
Publication of MX2021001606A publication Critical patent/MX2021001606A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
MX2021001606A 2018-08-14 2019-08-13 Tratamiento de la malignidades de las celulas b. MX2021001606A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201862718929P 2018-08-14 2018-08-14
US201862775797P 2018-12-05 2018-12-05
US201962836511P 2019-04-19 2019-04-19
PCT/US2019/046411 WO2020036999A1 (en) 2018-08-14 2019-08-13 Treatment of b cell malignancies

Publications (1)

Publication Number Publication Date
MX2021001606A true MX2021001606A (es) 2021-04-19

Family

ID=69525845

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021001606A MX2021001606A (es) 2018-08-14 2019-08-13 Tratamiento de la malignidades de las celulas b.

Country Status (14)

Country Link
US (1) US20210299134A1 (https=)
EP (1) EP3836935A4 (https=)
JP (1) JP2021534115A (https=)
KR (1) KR20210043635A (https=)
CN (1) CN112888441A (https=)
AU (1) AU2019321432A1 (https=)
BR (1) BR112021002760A2 (https=)
CA (1) CA3109184A1 (https=)
IL (1) IL280726A (https=)
MA (1) MA53236A (https=)
MX (1) MX2021001606A (https=)
SG (1) SG11202101450VA (https=)
TW (1) TW202021591A (https=)
WO (1) WO2020036999A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2608967T3 (es) 2011-03-28 2017-04-17 Mei Pharma, Inc. (Aralquilamino sustituido en alfa y heteroarilalquilamino)pirimidinil y 1,3,5-triazinil benzimidazoles, composiciones farmacéuticas que los contienen, y estos compuestos para usar en el tratamiento de enfermedades proliferativas
US11304953B2 (en) 2017-05-23 2022-04-19 Mei Pharma, Inc. Combination therapy
KR20200041358A (ko) 2017-08-14 2020-04-21 메이 파마, 아이엔씨. 병용 요법

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2648676A4 (en) * 2010-12-06 2016-05-04 Follica Inc METHODS FOR TREATING CALVITIA AND PROMOTING HAIR GROWTH
ES2608967T3 (es) * 2011-03-28 2017-04-17 Mei Pharma, Inc. (Aralquilamino sustituido en alfa y heteroarilalquilamino)pirimidinil y 1,3,5-triazinil benzimidazoles, composiciones farmacéuticas que los contienen, y estos compuestos para usar en el tratamiento de enfermedades proliferativas
PT3262071T (pt) * 2014-09-23 2020-06-16 H Hoffnabb La Roche Ag Métodos de utilização de imunoconjugados anti-cd79b
WO2017007658A1 (en) * 2015-07-07 2017-01-12 Rigel Pharmaceuticals, Inc. A combination for immune mediated cancer treatment
WO2017035234A1 (en) * 2015-08-24 2017-03-02 Epizyme, Inc. Method for treating cancer
EP3487878A4 (en) * 2016-07-20 2020-03-25 University of Utah Research Foundation CD229-CAR-T CELLS AND METHOD FOR USE THEREOF
CN109982687A (zh) * 2016-09-19 2019-07-05 梅制药公司 联合疗法
WO2018060833A1 (en) * 2016-09-27 2018-04-05 Novartis Ag Dosage regimen for alpha-isoform selective phosphatidylinositol 3-kinase inhibitor alpelisib
WO2018082444A1 (zh) * 2016-11-02 2018-05-11 叶宝欢 吡唑并嘧啶化合物作为pi3k抑制剂及其应用
KR20200041358A (ko) * 2017-08-14 2020-04-21 메이 파마, 아이엔씨. 병용 요법

Also Published As

Publication number Publication date
CA3109184A1 (en) 2020-02-20
EP3836935A1 (en) 2021-06-23
IL280726A (en) 2021-03-25
MA53236A (fr) 2021-06-23
US20210299134A1 (en) 2021-09-30
EP3836935A4 (en) 2022-09-14
BR112021002760A2 (pt) 2021-05-11
JP2021534115A (ja) 2021-12-09
SG11202101450VA (en) 2021-03-30
AU2019321432A1 (en) 2021-03-25
TW202021591A (zh) 2020-06-16
WO2020036999A1 (en) 2020-02-20
KR20210043635A (ko) 2021-04-21
CN112888441A (zh) 2021-06-01

Similar Documents

Publication Publication Date Title
BR112021022812A2 (pt) Dosagem de inibidor de kras para tratamento de cânceres
MX2021013218A (es) Composiciones y metodos para el tratamiento del cancer usando una terapia con celulas t modificadas con tet2.
MX2021000847A (es) Procedimientos para el tratamiento del cancer con el inhibidor de pi3k, gdc 0077.
MX2022014104A (es) Inhibidores de atr para el tratamiento del cancer.
PH12020551923A1 (en) Methods and compositions for treating cancer
ZA202107579B (en) Pharmaceutical combinations for the treatment of cancer
MX2020009773A (es) Terapia de combinacion.
PH12022551074A1 (en) Anti-cd47 and anti-cd20 based treatment of blood cancer
MX2020008906A (es) Compuestos con actividad inductora de ferroptosis y métodos de uso de estos.
EP4349412A3 (en) Methods for determining and achieving therapeutically effective doses of anti-cd47 agents in treatment of cancer
NZ628320A (en) Treatment of psoriatic arthritis using apremilast
MX2020001727A (es) Terapia de combinacion.
MX379621B (es) Combinacion de inhibidor de bcl-2 e inhibidor de mek para el tratamiento de cancer
NZ760459A (en) Receptor subtype and function selective retinoid and rexinoid compounds in combination with immune modulators for cancer immunotherapy
MX2019002925A (es) Modulacion inmune con agonistas de tlr9 para el tratamiento del cancer.
MX2019013862A (es) Terapia de combinacion.
MX2021001606A (es) Tratamiento de la malignidades de las celulas b.
PH12020552059A1 (en) Dosing regimen for the treatment of pi3k related disorders
MX2020003954A (es) Vectores lentivirales para suministro de pklr para el tratamiento de deficiencia de piruvato quinasa.
MX2015013177A (es) Combinacion de tratamientod de cancer usando microarns e inhibidores de egfr-tki.
MX390121B (es) Combinaciones de un inhibidor de btk y un inhibidor de pi3k para tratar neoplasias malignas hematológicas.
MX2016015161A (es) Metodos de tratamiento de cancer de mama luminal a positivo para pr con inhibidor de pi3k, pictilisib.
WO2019204332A3 (en) Pak4 inhibitors and methods of use
MX2021003734A (es) Métodos de tratamiento del linfoma de linfocitos t periférico mediante terapia con conjugado fármaco-anticuerpo anti-cd30.
MX2019003603A (es) Terapia de combinacion con un inhibidor de mek, un inhibidor del eje pd-1 y un taxano.